TL;DR
This study reveals how exosomes derived from adipose stem cells (ADSC-EXOs) accelerate diabetic wound healing. They achieve this by utilizing surface heat-shock protein 90 (eHSP90) to interact with the LRP1 receptor on skin cells, activating the AKT pathway to reduce oxidative stress, promote cell growth, and enhance tissue repair.
What Problem Does This Paper Address?
Diabetic wounds are a significant clinical challenge, often leading to delayed healing, amputation, and mortality. A key factor contributing to this poor healing is oxidative stress, exacerbated by high glucose and hypoxia, which damages skin cells and impairs the wound repair process. While stem cell-derived exosomes show promise for wound healing, the specific mechanisms by which they combat oxidative stress in the context of diabetic wounds remain unclear. This paper aims to elucidate how ADSC-EXOs promote diabetic wound healing, focusing on their role in mitigating oxidative stress and identifying the molecular pathways involved.
Methods
The researchers employed a multi-pronged approach:
- In vitro studies: They used cultured human keratinocytes (HaCaT), fibroblasts, and endothelial cells (HUVECs) to assess the effects of ADSC-EXOs on cell proliferation, migration, and angiogenesis. Oxidative stress and hypoxia were induced using hydrogen peroxide (H2O2) and cobalt chloride (CoCl2).
- Exosome characterization: ADSC-EXOs were isolated and characterized using transmission electron microscopy, nanoparticle tracking analysis, and Western blotting to confirm their size, morphology, and the presence of key exosomal markers (CD63, CD9, HSP70).
- Mechanism investigation:
- Internalization studies: PKH26-labeled ADSC-EXOs were used to track their uptake by different cell types, revealing limited uptake by fibroblasts.
- Proteomic analysis: Mass spectrometry was used to identify surface proteins on ADSC-EXOs, highlighting HSP90.
- Functional blocking assays: Anti-HSP90 antibodies were used to neutralize the effects of ADSC-EXOs.
- Signaling pathway analysis: Western blotting was employed to examine the activation of key signaling pathways (AKT, ERK, NF-κB) in response to ADSC-EXOs. Inhibitors for AKT (LY294002) and ERK (U0126) were used to dissect pathway involvement.
- Receptor identification: Gene silencing (shRNA) was used to knock down the low-density lipoprotein receptor-related protein 1 (LRP1) in fibroblasts to assess its role.
- In vivo studies: A full-thickness diabetic wound model in mice was established. ADSC-EXOs were injected locally around the wound sites, and their effects on wound closure, collagen deposition, neovascularization, ROS levels, and cell apoptosis were evaluated using histological and immunofluorescence analyses.
Datasets
Not discussed in the paper. The study primarily relies on in vitro cell cultures and an in vivo animal model.
Key Insights and Ideas
- Fibroblasts are tricky: ADSC-EXOs are not readily internalized by fibroblasts, suggesting their primary mode of action in these cells is through surface receptor interactions rather than direct uptake. This is a crucial distinction for understanding their therapeutic mechanism.
- eHSP90 is the key player: The study strongly implicates extracellular heat-shock protein 90 (eHSP90) on the exosome surface as the critical mediator of ADSC-EXO's beneficial effects. Neutralizing this protein significantly abrogates the protective and regenerative actions.
- LRP1 is the gatekeeper: The low-density lipoprotein receptor-related protein 1 (LRP1) on the fibroblast surface acts as the receptor for eHSP90, initiating downstream signaling.
- AKT pathway is the hero: The interaction between eHSP90 and LRP1 leads to the activation of the AKT signaling pathway, which is central to the observed improvements in cell survival, migration, and overall wound healing. The ERK pathway, while activated, did not appear to be the primary mediator of these specific benefits.
Key Results
- In vitro: ADSC-EXOs promoted proliferation, migration, and angiogenesis in keratinocytes, fibroblasts, and endothelial cells. They significantly reduced ROS levels and protected cells from hypoxia and oxidative stress-induced damage.
- In vivo: Local injection of ADSC-EXOs in diabetic mice significantly accelerated wound closure, increased collagen deposition and neovascularization, and reduced ROS levels and cell death.
- Mechanism: Blocking eHSP90 with an antibody abolished the protective effects of ADSC-EXOs. Knockdown of LRP1 in fibroblasts also impaired ADSC-EXO-mediated protection and migration. Inhibition of the AKT pathway with LY294002 mimicked the effects of LRP1 knockdown, confirming its central role.
Limitations and Future Work
- Limited fibroblast uptake: The minimal internalization of ADSC-EXOs by fibroblasts suggests that further research is needed to fully understand how these exosomes exert their effects on these specific cells, potentially focusing more on paracrine signaling or alternative uptake mechanisms.
- Other signaling pathways: While AKT and ERK were investigated, the authors acknowledge that other signaling pathways might also be involved in ADSC-EXO action and warrant further exploration.
- Translational potential: While promising, the study is preclinical. Future work would involve further validation in more complex models and eventual clinical translation to assess safety and efficacy in human patients.
- Specific HSP90 role: The study focused on eHSP90's role in mediating ADSC-EXO effects. Further investigation into the specific functions and interactions of HSP90 within the exosome and on the cell surface could provide deeper insights.
Summary updated